ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
promising Phase 2 QUILT-3.055 trial results at the IASLC World Conference on Lung Cancer, showing that ANKTIVA significantly reverses lymphopenia in advanced NSCLC patients resistant to checkpoint inhibitors. ImmunityBio's (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients Pressmaster/Shutterstock.com This immune restoration translated into prolonged median overall survival (mOS), with patients maintaining higher lymphocyte counts living up to 21.1 months. The therapy is being further evaluated in the Phase 3 ResQ201A trial alongside checkpoint inhibitor tislelizumab. ANKTIVA, a first-in-class IL-15 agonist fusion complex, activates NK and T cells depleted by standard cancer treatments. It mimics natural IL-15 receptor biology to restore immune memory and overcome tumor resistance. In the trial, 80% of patients exceeded an ALC of 1,200 cells/µL, with mOS of 15.8 months compared to 11.5 months in those who did not. These findings support ANKTIVA's role as a lymphoresto
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]Yahoo! Finance
- A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]Seeking Alpha
- A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Analyst Actions
- 9/10/25 - HC Wainwright
IBRX
Sec Filings
- 11/10/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- IBRX's page on the SEC website